Show simple item record

dc.contributor.advisorBarragan, Ana M. 
dc.creatorMilanés Escobar, Sonia Alejandra 
dc.creatorCuadrado Velásquez, Nelia Patricia 
dc.creatorDel Valle Zapata, Brenda Milena 
dc.date.accessioned2019-10-07T12:07:32Z
dc.date.available2019-10-07T12:07:32Z
dc.date.created2019-09-06
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/20396
dc.descriptionAntecedentes: El cáncer es una de las enfermedades crónicas con mayor morbimortalidad a nivel mundial. Se ha incrementado la preferencia de terapias alternativas en pacientes con cáncer como es la Amigdalina, pero se desconoce la extensión y naturaleza de la literatura respecto de ésta. Objetivo: Describir la naturaleza, variedad y extensión de la literatura alrededor del uso de Amigdalina en pacientes con cáncer. Metodología: Revisión sistemática de literatura de alcance. Se consultaron las bases MEDLINE a través de PUBMED, EMBASE, LILACS y literatura gris en google scholar. Se incluyeron estudios en humanos o tejido humano (in vitro) con cualquier tipo de cáncer, toda presentación y vías de administración de la Amigdalina. Tres revisores (SM, NC y BV) independientemente, tamizaron y extrajeron datos. Se sintetizó en: autores, año de publicación, país, tipo de estudio, tamaño de muestra, población y tipo de intervención. Resultados: De 2.402 referencias se removieron duplicados. En el tamizaje de título y resumen se excluyen 399 artículos. De 216 artículos completos se incluyeron 35 en la síntesis. Se reportaron revisiones narrativas (n = 15), estudios experimentales in vitro (n=12), reportes de casos (n=4), revisiones sistemáticas (n=2) y observacionales (n=2). El principal país en publicar fue Estados Unidos, seguido por Alemania. Discusión: No se recuperó toda la evidencia alrededor del uso de Amigdalina. Esto hace mas compleja la interpretación y el análisis de los datos recolectados. Conclusión: No hubo discrepancia entre los autores para no recomendar el uso de Amigdalina como tratamiento para pacientes con cáncer.
dc.description.abstractBackground: Cancer is one of the chronic diseases with the highest morbidity and mortality worldwide. The preference of alternative therapies in patients with cancer such as Amygdalin has increased, but the extent and nature of the literature regarding this is unknown. Objective: Describe the nature, variety and extent of the literature surrounding the use of Amygdalin in cancer patients. Methodology: Systematic review of scope literature. The MEDLINE bases were consulted through PUBMED, EMBASE, LILACS and gray literature in google scholar. Studies in human or human tissue (in vitro) with any type of cancer, all presentation and routes of administration of Amygdalin were included. Three reviewers (SM, NC and BV) independently screened and extracted data. It was synthesized in: authors, year of publication, country, type of study, sample size, population and type of intervention. Results: Duplicates were removed from 2,402 references. 399 articles are excluded in title and summary screening. Of 216 full articles, 35 were included in the synthesis. Narrative reviews (n=15), experimental in vitro studies (n=12), case reports (n=4), systematic reviews (n=2) and observational (n=2) were reported. The main country to publish was the United States, followed by Germany. Discussion: All evidence surrounding the use of Amygdalin was not recovered. This makes the interpretation and analysis of the data collected more complex. Conclusion: There was no discrepancy among the authors for not recommending the use of Amygdalin as a treatment for cancer patients.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsAtribución-SinDerivadas 2.5 Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nd/2.5/co/
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.subjectLaetrile
dc.subjectAmigdalina
dc.subjectAmigdalosida
dc.subjectNeoplasia
dc.subjectEfectividad
dc.subject.ddcCiencias médicas, Medicina 
dc.subject.lembMedicina
dc.subject.lembEpidemiología
dc.titleUso de Amigdalina en pacientes con cáncer: revisión sistemática de alcance
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Epidemiología (en Convenio con el CES)
dc.publisher.departmentFacultad de medicina
dc.subject.keywordLaetrile
dc.subject.keywordAmygdalin
dc.subject.keywordAmygdaloside
dc.subject.keywordNeoplasm
dc.subject.keywordEffectiveness
dc.rights.accesRightsinfo:eu-repo/semantics/embargoedAccess
dc.type.spaTrabajo de grado
dc.rights.accesoRestringido (Temporalmente bloqueado)
dc.description.embargo2019-10-07 07:15:01: Script de automatizacion de embargos. 7 de octubre El autor selecciona el tipo de acceso restringido, se asigna embargo por dos años. Se ha realizado la publicación de su documento "Uso de Amigdalina en pacientes con cáncer: revisión sistemática de alcance" en el Repositorio Institucional EdocUR de la Universidad del Rosario. Usted escogió la opción "Restringido (Temporalmente bloqueado)", por lo que el documento ha quedado con embargo hasta el 8 de octubre de 2021, en concordancia con las Políticas de Acceso Abierto de la Universidad. Si usted desea dejarlo con acceso abierto antes de finalizar dicho periodo o si por el contrario desea extender el embargo al finalizar este tiempo, puede enviar un correo a esta misma dirección realizando la solicitud. Tenga en cuenta que los documentos en acceso abierto propician una mayor visibilidad de su producción académica y científica. Se le envía correo 7 de octubre 2019 informando el tiempo de embargo del documento.
dc.date.embargoEndinfo:eu-repo/date/embargoEnd/2021-10-07
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationMuñoz NJM, Gómez FR, Martínez MLO, Lopez MGG. Instituto Nacional de Salud, Observatorio Nacional de Salud, Quinto Informe ONS: carga de enfermedad por enfermedades crónicas no transmisibles y discapacidad en Colombia. 2015;239. Available from: https://www.ins.gov.co/Direcciones/ONS/Informes/5. Carga de enfermedad ECNT.pdf
dc.source.bibliographicCitationFerlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J cancer [Internet]. 2015 Mar 1 [cited 2019 Jun 24];136(5):E359-86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25220842
dc.source.bibliographicCitationOPS/OMS. OPS/OMS | Programa de Cáncer [Internet]. 2019. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=292:cancer-program&Itemid=3904&lang=es
dc.source.bibliographicCitationWHO. El diagnóstico temprano del cáncer salva vidas y reduce los costos de tratamiento [Internet]. 2017. Available from: https://www.who.int/es/news-room/detail/03-02-2017-early-cancer-diagnosis-saves-lives-cuts-treatment-costs
dc.source.bibliographicCitationChu P-C, Hwang J-S, Wang J-D, Chang Y-Y. Estimation of the Financial Burden to the National Health Insurance for Patients with Major Cancers in Taiwan. J Formos Med Assoc [Internet]. 2008 Jan;107(1):54–63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S092966460860008X
dc.source.bibliographicCitationGonzález-Robledo MC, Wong R, Ornelas HA, Knaul FM. Costs of breast cancer care in Mexico: analysis of two insurance coverage scenarios. Ecancermedicalscience [Internet]. 2015 [cited 2019 Jun 25];9:587. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26557885
dc.source.bibliographicCitationCajaraville J Carreras J Massó M J Tamés GM. Sociedad española de farmacia hospitalaria .Oncologia, Capitulo 14. [cited 2019 Jul 3]; Available from: https://www.sefh.es/bibliotecavirtual/fhtomo2/CAP14.pdf
dc.source.bibliographicCitationPaul Symonds R, Foweraker K. Principles of chemotherapy and radiotherapy. Curr Obstet Gynaecol [Internet]. 2006 Apr 1 [cited 2019 Jun 24];16(2):100–6. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0957584706000205
dc.source.bibliographicCitationSilvia Aibar et al. Manual de enfermería oncologica Instituto Nacional del Cáncer [Internet]. [cited 2019 Aug 27]. p. Pagina 23-29. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000011cnt-08-manual enfermeria_08-03.pdf
dc.source.bibliographicCitationSadeghi M, Enferadi M, Shirazi A. External and internal radiation therapy: Past and future directions. J Cancer Res Ther [Internet]. 2010 [cited 2019 Jun 24];6(3):239. Available from: http://www.cancerjournal.net/text.asp?2010/6/3/239/73324
dc.source.bibliographicCitationCancer Reserach UK. Tratamiento para el cáncer | Cáncer en general | Cancer Research UK [Internet]. [cited 2019 Jul 7]. Available from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment
dc.source.bibliographicCitationIrmak Z, Tanrıverdi Ö, Ödemiş H, Demir Uysal D. Use of complementary and alternative medicine and quality of life of cancer patients who received chemotherapy in Turkey. Complement Ther Med [Internet]. 2019 [cited 2019 Jul 10];44:143–50. Available from: www.elsevier.com/locate/ctim
dc.source.bibliographicCitationGzell C, Back M, Wheeler H, Bailey D, Foote M. Radiotherapy in Glioblastoma: the Past, the Present and the Future. Clin Oncol [Internet]. 2017 Jan [cited 2019 Sep 5];29(1):15–25. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0936655516303168
dc.source.bibliographicCitationLongo DL (Dan L, Based on (expression): Harrison TR. Harrison’s hematology and oncology. XIX. New York : McGraw-Hill Education Medical, [2017]; 2017. 832 p.
dc.source.bibliographicCitationCalderillo Ruiz Miguel Quintana Quintana G. ONCOLOGÍA GENERAL PARA PROFESIONALES DE LA SALUD DE PRIMER CONTACTO [Internet]. Ciudad de Mexico; 2017 [cited 2019 Aug 27]. Available from: www.permanyer.com
dc.source.bibliographicCitationMustian KM, Sprod LK, Janelsins M, Peppone LJ, Mohile S. Exercise Recommendations for Cancer-Related Fatigue, Cognitive Impairment, Sleep problems, Depression, Pain, Anxiety, and Physical Dysfunction: A Review. Oncol Hematol Rev [Internet]. 2012 [cited 2019 Jul 10];8(2):81–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23667857
dc.source.bibliographicCitationCrawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. N Engl J Med [Internet]. 1991 Jul 18 [cited 2019 Jul 7];325(3):164–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1711156
dc.source.bibliographicCitationAsociación Española Contra el Cáncer. Tipos de terapias alternativas [Internet]. [cited 2019 Sep 5]. Available from: https://www.aecc.es/es/todo-sobre-cancer/tratamientos/otros-tratamientos/tipos-terapias-alternativas
dc.source.bibliographicCitationRyan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: A URCC CCOP study of 576 patients. Support Care Cancer [Internet]. 2012 Jul [cited 2019 Sep 5];20(7):1479. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21818642
dc.source.bibliographicCitationGeiger JL. The essential oil of ginger, Zingiber officinale, and anaesthesia. Int J Aromather [Internet]. 2005 Jan 1 [cited 2019 Sep 5];15(1):7–14. Available from: https://www.sciencedirect.com/science/article/pii/S0962456204001213
dc.source.bibliographicCitationGarcía-García RM, Palou-García E. Temas Selectos de Ingeneria de Alımentos.
dc.source.bibliographicCitationFenselau C, Pallante S, Batzinger RP, Benson WR, Barron RP, Sheinin EB, et al. Mandelonitrile beta-glucuronide: synthesis and characterization. Science (80- ) [Internet]. 1977 Nov 11 [cited 2019 Jul 6];198(4317):625. Available from: http://science.sciencemag.org/content/198/4317/625.abstract
dc.source.bibliographicCitationStrugala GJ, Rauws AG, Elbers R. Intestinal first pass metabolism of amygdalin in the rat in vitro. Biochem Pharmacol [Internet]. 1986 Jul 1 [cited 2019 Jun 25];35(13):2123–8. Available from: https://www.sciencedirect.com/science/article/abs/pii/0006295286905800
dc.source.bibliographicCitationPark H-J, Yoon S-H, Han L-S, Zheng L-T, Jung K-H, Uhm Y-K, et al. Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells. World J Gastroenterol [Internet]. 2005 Sep 7 [cited 2019 Jul 11];11(33):5156–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16127745
dc.source.bibliographicCitationMani J, Rutz J, Maxeiner S, Juengel E, Bon D, Roos F, et al. Cyanide and lactate levels in patients during chronic oral amygdalin intake followed by intravenous amygdalin administration. Complement Ther Med [Internet]. 2019 [cited 2019 Jun 25];43:295–9. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2001686031
dc.source.bibliographicCitationMoertel CG, Ames MM, Kovach JS, Moyer TP, Rubin JR, Tinker JH. A pharmacologic and toxicological study of amygdalin. JAMA. 1981 Feb;245(6):591–4.
dc.source.bibliographicCitationJiagang D, Li C, Wang H, Hao E, Du Z, Bao C, et al. Amygdalin mediates relieved atherosclerosis in apolipoprotein E deficient mice through the induction of regulatory T cells. Biochem Biophys Res Commun [Internet]. 2011 Aug 5 [cited 2019 Jul 11];411(3):523–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21756879
dc.source.bibliographicCitationPeters M, Godfrey C, Khalil H, Mcinerney P, Soares C, Parker D. 2017 Guidance for the Conduct of JBI Scoping Reviews. In 2017.
dc.source.bibliographicCitationLi Qiang, Xu Xiaoqin, Li Yan DH. Study on Acid Hydrolysis Condition of Amygdalin--《Modern Chinese Medicine》2009年01期 [Internet]. 2009. [cited 2019 Jul 11]. Available from: http://en.cnki.com.cn/Article_en/CJFDTotal-YJXX200901013.htm
dc.source.bibliographicCitationUrry LA, Cain ML, Wasserman SA, Minorsky P V., Reece JB. Campbell Biology in Focus + Masteringbiology With Etext Access Card. Benjamin-Cummings Pub Co; 2015.
dc.source.bibliographicCitationKroemer G, Pouyssegur J. Tumor Cell Metabolism: Cancer’s Achilles’ Heel. Cancer Cell [Internet]. 2008 Jun [cited 2019 Aug 28];13(6):472–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18538731
dc.source.bibliographicCitationWarburg O. On the Origin of Cancer Cells. Science (80- ). 1956 Feb;123(3191):309–14.
dc.source.bibliographicCitationFunes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci [Internet]. 2007 Apr 10 [cited 2019 Aug 29];104(15):6223–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17384149
dc.source.bibliographicCitationPark J-H, Seo B-I, Cho S-Y, Park K-R, Choi S-H, Han C-K, et al. Single oral dose toxicity study of prebrewed armeniacae semen in rats. Toxicol Res [Internet]. 2013 Jun 30 [cited 2019 Aug 5];29(2):91–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24278634
dc.source.bibliographicCitationSwietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev [Internet]. 2007 Jul 24 [cited 2019 Aug 29];26(2):299–310. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17415526
dc.source.bibliographicCitationFischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood [Internet]. 2007 May 1 [cited 2019 Aug 29];109(9):3812–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17255361
dc.source.bibliographicCitationKoukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma. Cancer Res [Internet]. 2006 Jan 15 [cited 2019 Aug 29];66(2):632–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16423989
dc.source.bibliographicCitationDenko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008 Sep;8(9):705–13.
dc.source.bibliographicCitationKaelin WG, Thompson CB. Clues from cell metabolism. Nature. 2010 Jun;465(7298):562–4.
dc.source.bibliographicCitationWu K, Yang M. Epithelial–mesenchymal transition and cancer stemness: the Twist1–Bmi1 connection. Biosci Rep. 2011 Dec;31(6):449–55.
dc.source.bibliographicCitationSingleterry J, Sreedhar A, Zhao Y. Components of cancer metabolism and therapeutic interventions. Mitochondrion. 2014 Jul;17:50–5.
dc.source.bibliographicCitationHsu PP, Sabatini DM. Cancer Cell Metabolism: Warburg and Beyond. Cell. 2008 Sep;134(5):703–7.
dc.source.bibliographicCitationJ. S, Q. C, M. X, Q. X, T. Z, J. T, et al. Recent updates and future perspectives about amygdalin as a potential anticancer agent: A review. Cancer Med [Internet]. 2019;8(6):3004–11. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L628102327
dc.source.bibliographicCitationX Y. Advances in anti‐tumor mechanism of Guangxi Chinese herbal medicine. J Liaoning Univ Tradit Chin Med. 2012;14((05)):60–2.
dc.source.bibliographicCitationOrlikova B, Legrand N, Panning J et al. Anti‐inflammatory and anticancer drugs from nature. Cancer Treat Res. 2014;159:123–43.
dc.source.bibliographicCitationLea MA, Koch MR. Effects of cyanate, thiocyanate, and amygdalin on metabolite uptake in normal and neoplastic tissues of the rat. J Natl Cancer Inst. 1979 Nov;63(5):1279–83.
dc.source.bibliographicCitationMakarević J, Tsaur I, Juengel E, Borgmann H, Nelson K, Thomas C, et al. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci [Internet]. 2016 Feb 15 [cited 2019 Jul 11];147:137–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26827990
dc.source.bibliographicCitationA.C. T, I. K, I. R, D. Z, D.M.-Y. S. Potential antioxidant, antiinflammatory, and proapoptotic anticancer activities of Kakadu plum and Illawarra plum polyphenolic fractions. Nutr Cancer [Internet]. 2011;63(7):1074–84. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L362711925
dc.source.bibliographicCitationBasu TK. High-dose ascorbic acid decreases detoxification of cyanide derived from amygdalin (laetrile): studies in guinea pigs. Can J Physiol Pharmacol. 1983 Nov;61(11):1426–30.
dc.source.bibliographicCitationMiller KW, Anderson JL, Stoewsand GS. Amygdalin metabolism and effect on reproduction of rats fed apricot kernels. J Toxicol Environ Health. 1981;7(3–4):457–67.
dc.source.bibliographicCitationX N. Research Progress of Amygdalin. Nei Mong J Tradit Chin Med. 2012;31(9):66‐67.
dc.source.bibliographicCitationLee H, Moon A. Amygdalin regula la apoptosis y la adhesión en células de cáncer de mama triple negativo Hs578T. Biomol Ther (Seoul) [Internet]. 2016 [cited 2019 Aug 10]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703354/
dc.source.bibliographicCitationTang F, Fan K, Wang K, Bian C. Amygdalin attenuates acute liver injury induced by D-galactosamine and lipopolysaccharide by regulating the NLRP3, NF-κB and Nrf2/NQO1 signalling pathways. Biomed Pharmacother [Internet]. 2019 Mar 1 [cited 2019 Jul 11];111:527–36. Available from: https://www.sciencedirect.com/science/article/pii/S075333221833693X?via%3Dihub
dc.source.bibliographicCitationA. Z, W. P, J. L, H. W, Zhang A, Pan W, et al. Protective Effect of Amygdalin on LPS-Induced Acute Lung Injury by Inhibiting NF-κB and NLRP3 Signaling Pathways. Inflammation [Internet]. 2017 Jun;40(3):1–7. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617935203
dc.source.bibliographicCitationP. L, B. B. Molecular mechanism of amygdalin action in vitro: review of the latest research. Immunopharmacol Immunotoxicol [Internet]. 2018;40(3):212–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L622211455
dc.source.bibliographicCitationA E, Z F, H H, I I, M K, M O. Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews. In: Abstracts of the 22nd Cochrane Colloquium. John Wiley & Sons; 2014. p. 9.
dc.source.bibliographicCitationTricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med [Internet]. 2018 Oct 2 [cited 2019 Sep 6];169(7):467. Available from: http://annals.org/article.aspx?doi=10.7326/M18-0850
dc.source.bibliographicCitationHorneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How Many Cancer Patients Use Complementary and Alternative Medicine: A Systematic Review and Metaanalysis. Integr Cancer Ther [Internet]. 2011 Jun 6 [cited 2019 Jul 3];11(3):187–203. Available from: http://ict.sagepub.com
dc.source.bibliographicCitationMoertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, et al. A Clinical Trial of Amygdalin (Laetrile) in the Treatment of Human Cancer. N Engl J Med [Internet]. 1982 Jan 2 [cited 2019 Jul 21];306(4):201–6. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM198201283060403
dc.source.bibliographicCitationC. F, R. B, L. B, J. VE, Faw C, Ballentine R, et al. Unproved cancer remedies. A survey of use in pediatric outpatients. J Am Med Assoc [Internet]. 1977 Oct;238(14):1536–8. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L8204633
dc.source.bibliographicCitationMilazzo S, Lejeune S, Ernst E. Laetrile for cancer: a systematic review of the clinical evidence. Support Care Cancer [Internet]. 2007;15(6):583–95. Available from: http://dx.doi.org/10.1007/s00520-006-0168-9
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.type.emcsRevisión sistemática
dc.creator.degreetypeFull time
dc.contributor.coadvisorOndo-Méndez, Alejandro 


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-SinDerivadas 2.5 Colombia

 

Reconocimientos: